ATE299031T2 - Neue exendin agonist formulierungen und deren verabreichung - Google Patents

Neue exendin agonist formulierungen und deren verabreichung Download PDF

Info

Publication number
ATE299031T2
ATE299031T2 AT00914425T AT00914425T ATE299031T2 AT E299031 T2 ATE299031 T2 AT E299031T2 AT 00914425 T AT00914425 T AT 00914425T AT 00914425 T AT00914425 T AT 00914425T AT E299031 T2 ATE299031 T2 AT E299031T2
Authority
AT
Austria
Prior art keywords
administration
exendin agonist
agonist formulations
methods
new exendin
Prior art date
Application number
AT00914425T
Other languages
English (en)
Inventor
Andrew Young
Italien James J L
Orville Kolterman
Original Assignee
Amylin Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26814176&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE299031(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amylin Pharmaceuticals Inc filed Critical Amylin Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE299031T2 publication Critical patent/ATE299031T2/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Peptides Or Proteins (AREA)
AT00914425T 1999-01-14 2000-01-14 Neue exendin agonist formulierungen und deren verabreichung ATE299031T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11638099P 1999-01-14 1999-01-14
US17536500P 2000-01-10 2000-01-10
PCT/US2000/000902 WO2000041546A2 (en) 1999-01-14 2000-01-14 Novel exendin agonist formulations and methods of administration thereof

Publications (1)

Publication Number Publication Date
ATE299031T2 true ATE299031T2 (de) 2005-07-15

Family

ID=26814176

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00914425T ATE299031T2 (de) 1999-01-14 2000-01-14 Neue exendin agonist formulierungen und deren verabreichung

Country Status (21)

Country Link
US (1) US6902744B1 (de)
EP (2) EP1609478A1 (de)
JP (1) JP4426727B2 (de)
KR (1) KR100675711B1 (de)
CN (2) CN101181236A (de)
AT (1) ATE299031T2 (de)
AU (2) AU777564B2 (de)
BR (1) BRPI0007820B8 (de)
CA (1) CA2356706C (de)
CY (1) CY2007013I2 (de)
DE (3) DE60021166T3 (de)
DK (1) DK1140145T4 (de)
ES (1) ES2244416T5 (de)
HK (1) HK1040635B (de)
LU (1) LU91343I2 (de)
NL (1) NL300282I1 (de)
NO (2) NO331382B1 (de)
NZ (1) NZ512663A (de)
PT (1) PT1140145E (de)
RU (1) RU2242244C2 (de)
WO (1) WO2000041546A2 (de)

Families Citing this family (150)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69739172D1 (de) * 1996-08-08 2009-01-29 Amylin Pharmaceuticals Inc Regulation gastrointestinaler beweglichkeit
PT1629849E (pt) * 1997-01-07 2013-07-09 Amylin Pharmaceuticals Llc Composições farmacêuticas que compreendem exendinas e seus agonistas
US20030087820A1 (en) * 1999-01-14 2003-05-08 Young Andrew A. Novel exendin agonist formulations and methods of administration thereof
US7399489B2 (en) * 1999-01-14 2008-07-15 Amylin Pharmaceuticals, Inc. Exendin analog formulations
EP1658856B1 (de) 1999-01-14 2010-03-17 Amylin Pharmaceuticals, Inc. Exendine zur Glucagon Suppression
US20090175821A1 (en) * 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
US6514500B1 (en) * 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
EP1346722B1 (de) 2000-12-01 2008-12-10 Takeda Pharmaceutical Company Limited Verfahren zur herstellung einer zubereitung mit einer bioaktiven substanz
US20030119734A1 (en) 2001-06-28 2003-06-26 Flink James M. Stable formulation of modified GLP-1
JP2005501058A (ja) 2001-07-31 2005-01-13 ザ ガバメント オブ ザ ユナイテッドステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ ザ ナショナル インステ Ｇｌｐ−１、ｅｘｅｎｄｉｎ−４、そのペプチド・アナログ及びその使用
KR20040054729A (ko) * 2001-10-18 2004-06-25 브리스톨-마이어스 스큅 컴퍼니 인간 글루카곤-유사-펩티드-1 모방체, 및 당뇨병 및 이와관련된 증상의 치료에 있어서 이의 용도
DE10238931C1 (de) * 2002-08-24 2003-07-31 Fh Hildesheim Holzminden Goe Verfahren und Vorrichtung zur Vorbereitung eines Finger- oder Fußnagels für eine Beschichtung, insbesondere Lackierung
MXPA05004202A (es) * 2002-10-22 2005-09-20 Waratah Pharmaceuticals Inc Tratamiento de la diabetes.
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
CN1771080B (zh) 2003-04-08 2010-12-15 诺沃挪第克公司 包括至少一个色谱处理步骤的生产治疗用多肽或其前体的方法
WO2004089985A1 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S Stable pharmaceutical compositions
ES2425221T3 (es) * 2003-05-30 2013-10-14 Amylin Pharmaceuticals, Llc Nuevos métodos y composiciones para suministro por vía transmucosa potenciado de péptidos y proteínas
WO2004105790A1 (en) 2003-06-03 2004-12-09 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
JP4936884B2 (ja) 2003-06-03 2012-05-23 ノボ・ノルデイスク・エー／エス 安定化された薬学的ペプチド組成物
CN1812808B (zh) 2003-06-03 2012-07-04 诺沃挪第克公司 稳定化的药物肽组合物
DE10329324A1 (de) * 2003-06-30 2005-02-03 Toximed Gmbh Pharmarzeutischer Schlankmacher
EP1663295A2 (de) * 2003-09-01 2006-06-07 Novo Nordisk A/S Stabilisierte peptidformulierungen
PT1687019T (pt) 2003-11-20 2018-02-26 Novo Nordisk As Formulações de péptidos que contêm polietileno glicol que são ótimas para produção e para utilização em dispositivos de injeção
CA2550695A1 (en) * 2003-12-16 2005-06-30 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R Glp-1 pharmaceutical compositions
US20090202494A1 (en) * 2004-01-30 2009-08-13 Antonio Cruz Combined use of glp-1 agonists and gastrin for regulating blood glucose levels
CA2564031A1 (en) * 2004-04-23 2005-11-03 Conjuchem Biotechnologies Inc. Method for the purification of albumin conjugates
WO2005117584A2 (en) * 2004-05-28 2005-12-15 Amylin Pharmaceuticals, Inc Improved transmucosal delivery of peptides and proteins
EP1789434B1 (de) 2004-08-31 2013-11-20 Novo Nordisk A/S Verwendung von tris(hydroxymethyl)-aminomethan zur stabilisierung von peptiden, polypeptiden und proteinen
EP2494983B1 (de) 2004-11-12 2019-04-24 Novo Nordisk A/S Stabile formulierung von glp-1
EP1841448A2 (de) * 2004-12-30 2007-10-10 Diakine Therapeutics, Inc. Pharmazeutische zusammensetzungen und vefahren zur wiederherstellung der betazellmasse und funktion
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
EP1889618A4 (de) * 2005-05-27 2010-11-24 Daiichi Sankyo Co Ltd Kombiniertes arzneimittel zur behandlung von diabetes
LT2347762T (lt) 2005-08-19 2019-08-26 Amylin Pharmaceuticals, Llc Eksendinas, skirtas diabeto gydymui ir kūno svorio mažinimui
US8039432B2 (en) * 2005-11-09 2011-10-18 Conjuchem, Llc Method of treatment of diabetes and/or obesity with reduced nausea side effect
EP1976876A4 (de) * 2005-12-22 2010-01-13 Conjuchem Biotechnologies Inc Verfahren zur herstellung von vorgebildeten konjugaten von albumin und einem therapeutischen mittel
AU2006328328B2 (en) 2005-12-22 2012-08-30 Takeda Pharmaceutical Company Limited Solid preparation containing an insulin sensitizer
AU2007267833B2 (en) * 2006-05-26 2012-07-26 Amylin Pharmaceuticals, Llc Composition and methods for treatment of congestive heart failure
KR101106510B1 (ko) 2006-05-30 2012-01-20 인타르시아 세라퓨틱스 인코포레이티드 투피스, 내부채널 삼투압 전달 시스템 유동 조절기
CA2670821C (en) 2006-08-09 2012-05-15 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
EP2056673A4 (de) * 2006-08-17 2010-06-16 Wellstat Therapeutics Corp Kombinationsbehandlung für stoffwechselerkrankungen
CN102827284B (zh) * 2006-11-14 2015-07-29 上海仁会生物制药股份有限公司 带有聚乙二醇基团的Exendin或其类似物及其制剂和用途
RU2413528C2 (ru) 2007-01-18 2011-03-10 Открытое Акционерное Общество "Валента Фармацевтика" Лекарственный препарат для лечения сахарного диабета на основе экзенатида и даларгина, применение и способ лечения
KR100805208B1 (ko) * 2007-03-27 2008-02-21 주식회사 펩트론 엑센딘 함유 서방성 제제 조성물, 엑센딘 함유 서방성미립구 및 이의 제조 방법
CA2683610C (en) * 2007-04-23 2013-01-08 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
JP5496082B2 (ja) * 2007-04-30 2014-05-21 ノボ・ノルデイスク・エー／エス タンパク質組成物を乾燥させる方法、乾燥タンパク質組成物、及び乾燥タンパク質を含有する薬学的組成物
CN101366692A (zh) * 2007-08-15 2009-02-18 江苏豪森药业股份有限公司 一种稳定的艾塞那肽制剂
CN101444618B (zh) * 2007-11-26 2012-06-13 杭州九源基因工程有限公司 含有艾塞那肽的药物制剂
US20090186819A1 (en) * 2007-12-11 2009-07-23 Marieve Carrier Formulation of insulinotropic peptide conjugates
WO2009102467A2 (en) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
CN102027005A (zh) 2008-05-15 2011-04-20 诺沃-诺迪斯克有限公司 通过固相合成制备的肽的纯化
WO2009143285A2 (en) 2008-05-21 2009-11-26 Amylin Pharmaceuticals, Inc. Exendins to lower cholestrol and triglycerides
US8742082B2 (en) * 2008-08-14 2014-06-03 Nestec S.A. Compositions and methods for influencing satiety, lipid metabolism, and fat utilization
PT3228320T (pt) 2008-10-17 2020-03-26 Sanofi Aventis Deutschland Combinação de uma insulina e de um agonista do glp-1
CN101870728A (zh) 2009-04-23 2010-10-27 派格生物医药(苏州)有限公司 新型Exendin变体及其缀合物
EP2435061A4 (de) 2009-05-28 2013-03-27 Amylin Pharmaceuticals Inc Schlaffördernde glp-1-rezeptor-agonistenverbindungen
KR101853606B1 (ko) 2009-07-06 2018-05-03 사노피-아벤티스 도이칠란트 게엠베하 메티오닌을 함유하는 수성 인슐린 제제
CN101642562A (zh) * 2009-08-28 2010-02-10 江苏万邦生化医药股份有限公司 艾塞那肽药用制剂及注射液的制备方法
MX378797B (es) 2009-09-28 2025-03-10 Intarcia Therapeutics Inc Establecimiento y/o terminacion rapidos de suministro de estado estable sustancial de farmaco.
DK2498802T3 (en) 2009-11-13 2015-04-13 Sanofi Aventis Deutschland Pharmaceutical composition comprising a GLP-1 agonist, insulin and a methionine
KR101337322B1 (ko) 2009-11-13 2013-12-06 사노피-아벤티스 도이칠란트 게엠베하 Ｇｌｐ-1 효능제 및 메티오닌을 포함하는 약제학적 조성물
WO2011064316A2 (en) 2009-11-25 2011-06-03 Paolo Botti Mucosal delivery of peptides
CN102100912B (zh) * 2009-12-16 2015-04-22 上海蓝心医药科技有限公司 一种给药组合物及其制备和使用方法
US9168288B2 (en) 2010-04-09 2015-10-27 Mount Sinai Hospital Methods for treating disorders of the gastrointestinal tract using a GLP-1 agonist
CA2797133C (en) 2010-04-27 2019-08-06 Zealand Pharma A/S Peptide conjugates of glp-1 receptor agonists and gastrin and their use
NZ603399A (en) 2010-05-17 2014-09-26 Cebix Inc Pegylated c-peptide
ES2606554T3 (es) 2010-08-30 2017-03-24 Sanofi-Aventis Deutschland Gmbh Uso de AVE0010 para la fabricación de un medicamento para el tratamiento de la diabetes mellitus de tipo 2
CN102397558B (zh) * 2010-09-09 2013-08-14 中国人民解放军军事医学科学院毒物药物研究所 Exendin-4类似物的定位聚乙二醇化修饰物及其用途
EP2438930A1 (de) * 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Prodrug mit einem exendinbindenden Konjugat
EA201390450A1 (ru) 2010-09-28 2013-07-30 Амилин Фармасьютикалс, Ллк. Полипептиды с увеличенной продолжительностью действия
EP2654767A4 (de) 2010-12-22 2014-05-21 Amylin Pharmaceuticals Inc Glp-1-rezeptoragonisten zur inselzelltransplantation
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
CN102100906A (zh) * 2011-02-18 2011-06-22 深圳翰宇药业股份有限公司 一种艾塞那肽的药用制剂及其制备方法
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
US20140221282A1 (en) 2011-05-25 2014-08-07 Astrazeneca Pharmaceuticals Lp Long duration dual hormone conjugates
EP2526971A1 (de) 2011-05-25 2012-11-28 ArisGen SA Mukosale Freisetzung von Arzneimitteln
EP2713722B1 (de) 2011-05-31 2017-03-15 Receptos, LLC Neue glp-1-rezeptor-stabilisatoren und -modulatoren
JP6006309B2 (ja) 2011-07-08 2016-10-12 アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド
PL2750699T3 (pl) 2011-08-29 2015-12-31 Sanofi Aventis Deutschland Kombinacja farmaceutyczna do stosowania w kontroli glikemii u pacjentów z cukrzycą typu 2
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
TW201326194A (zh) 2011-11-03 2013-07-01 Zealand Pharma As Ｇｌｐ－１胃泌素受體促效劑肽結合物
WO2013075117A2 (en) 2011-11-17 2013-05-23 John Wahren Pegylated c-peptide
ES2836973T3 (es) 2011-12-12 2021-06-28 Receptos Llc Derivados de ácido carboxílico que comprenden cuatro ciclos que actúan como moduladores de receptor GLP-1 para la terapia de enfermedades tales como la diabetes
WO2013182217A1 (en) * 2012-04-27 2013-12-12 Sanofi-Aventis Deutschland Gmbh Quantification of impurities for release testing of peptide products
WO2013170636A1 (zh) 2012-05-18 2013-11-21 爱德迪安（北京）生物技术有限公司 用于糖尿病治疗的蛋白、蛋白缀合物及其应用
MX356957B (es) 2012-07-23 2018-06-20 Zealand Pharma As Analogos del glucagon.
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
EP2915817B1 (de) 2012-10-31 2018-06-20 Hybio Pharmaceutical Co., Ltd. Verfahren zur herstellung von exenatid
CN102977204A (zh) * 2012-11-14 2013-03-20 吉林省敖腾生物科技有限责任公司 一种固相合成glp-1类似物的方法
JP2016506401A (ja) 2012-12-21 2016-03-03 サノフイ 二重ｇｌｐ１／ｇｉｐまたは三方ｇｌｐ１／ｇｉｐ／グルカゴンアゴニストとしてのエキセンジン−４誘導体
MX369511B (es) 2013-04-03 2019-11-11 Sanofi Sa Tratamiento de la diabetes mellitus mediante formulaciones de insulinas de acción prolongada.
BR112015031040A8 (pt) 2013-06-11 2018-01-02 Receptos Inc Novos moduladores do receptor de glp-1
CN103405753B (zh) * 2013-08-13 2016-05-11 上海仁会生物制药股份有限公司 稳定的促胰岛素分泌肽水针药物组合物
LT3057984T (lt) 2013-10-17 2018-12-27 Zealand Pharma A/S Acilinti gliukagono analogai
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
AU2014345569B2 (en) 2013-11-06 2020-08-13 Zealand Pharma A/S GIP-GLP-1 dual agonist compounds and methods
KR102310392B1 (ko) 2013-11-06 2021-10-13 질랜드 파마 에이/에스 글루카곤-ｇｌｐ-1-ｇｉｐ 삼원 효능제 화합물
CN112043835B (zh) 2013-12-06 2022-10-21 韩捷 用于含氮和羟基的药物的生物可逆引入基团
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
TW201609796A (zh) 2013-12-13 2016-03-16 賽諾菲公司 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
EP3080150B1 (de) 2013-12-13 2018-08-01 Sanofi Exendin-4-peptidanaloga als duale glp-1/gip-rezeptoragonisten
TW201609799A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／ｇｉｐ受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
US9474755B2 (en) 2014-07-25 2016-10-25 Celgene International Ii Sarl GLP-1 receptor modulators
GB201415598D0 (en) 2014-09-03 2014-10-15 Univ Birmingham Elavated Itercranial Pressure Treatment
WO2016037128A1 (en) * 2014-09-04 2016-03-10 Nano Precision Medical, Inc. Polymeric stabilizing formulations
US12071516B2 (en) 2014-09-04 2024-08-27 Nano Precision Medical, Inc. Polymeric stabilizing formulations
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
RU2716985C2 (ru) 2014-10-29 2020-03-17 Зилэнд Фарма А/С Соединения-агонисты gip и способы
CA2969944A1 (en) 2014-12-10 2016-06-16 Celgene International Ii Sarl Glp-1 receptor modulators
AU2015359376B2 (en) 2014-12-12 2021-09-09 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
HK1249847A1 (zh) 2015-03-09 2018-11-16 Intekrin Therapeutics, Inc. 用於治疗非酒精性脂肪肝疾病和/或脂肪营养不良的方法
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
JP6989385B2 (ja) 2015-04-16 2022-01-05 ジーランド ファーマ アクティーゼルスカブ アシル化グルカゴン類似体
SMT202100668T1 (it) 2015-05-22 2022-01-10 Univ Leland Stanford Junior Trattamento dell'ipoglicemia post-bariatrica con antagonisti del glp-1
CN113598842A (zh) 2015-06-03 2021-11-05 因塔西亚制药公司 植入物放置和移除系统
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
CN106554403B (zh) 2015-09-25 2021-08-31 博瑞生物医药（苏州）股份有限公司 艾塞那肽修饰物及其用途
CR20180378A (es) 2015-12-23 2018-12-06 Amgen Inc Método para tratar o mejorar trastornos metabólicos con proteínas de unión para el receptor peptídico inhibidor gástrico (gipr) en combinación con agosnistas de glp-1
US10653753B2 (en) 2016-03-04 2020-05-19 Eiger Biopharmaceuticals, Inc. Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
KR102574993B1 (ko) 2016-05-16 2023-09-06 인타르시아 세라퓨틱스 인코포레이티드 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
US20190224122A1 (en) * 2016-09-23 2019-07-25 Delpor, Inc. Stable compositions for incretin mimetic compounds
CN107952064B (zh) * 2016-10-14 2023-10-20 江苏豪森药业集团有限公司 含有聚乙二醇洛塞那肽的药物制剂及其制备方法
JP7584894B2 (ja) 2016-11-21 2024-11-18 アイガー・バイオファーマシューティカルズ・インコーポレイテッド エキセンディン（９－３９）の緩衝製剤
US11285180B2 (en) 2016-12-06 2022-03-29 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods of enhancing the potency of incretin-based drugs in subjects in need thereof
SG10201911851VA (en) 2016-12-09 2020-02-27 Zealand Pharma As Acylated glp-1/glp-2 dual agonists
WO2018129058A1 (en) 2017-01-03 2018-07-12 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug
KR102781241B1 (ko) 2017-01-17 2025-03-14 암젠 인크 위 저해 펩타이드 수용체(gipr)에 대한 길항제에 접합된 glp-1 수용체 작용제를 사용하여 대사 장애를 치료 또는 개선하는 방법
KR20200036808A (ko) 2017-04-03 2020-04-07 코히러스 바이오사이언시스, 인크. 진행성 핵상 마비 치료를 위한 PPARγ 작용제
MX2019013919A (es) 2017-06-20 2020-01-21 Amgen Inc Metodo para tratar o mejorar trastornos metabolicos con proteinas de union para el receptor peptidico inhibidor gastrico (gipr) en combinacion con agonistas de glp-1.
JP7250706B2 (ja) 2017-06-21 2023-04-03 アムジエン・インコーポレーテツド 胃抑制ペプチド受容体（ｇｉｐｒ）に対するアンタゴニスト結合タンパク質／ｇｌｐ－１受容体アゴニスト融合タンパク質を使用した代謝障害の治療又は寛解方法
HUE066356T2 (hu) 2017-08-24 2024-07-28 Novo Nordisk As GLP-1 készítmények és alkalmazásaik
RU2666148C1 (ru) * 2017-10-05 2018-09-06 Общество с ограниченной ответственностью "Новые Антибиотики" Способ получения водорастворимой лиофилизированной формы соли бис(2-тио-4,6-диоксо-1,2,3,4,5,6-гексагидропиримидин-5-ил)-(4-нитрофенил)метана
EP3934679A1 (de) 2019-03-08 2022-01-12 Amgen Inc. Kombinationstherapie mit wachstumsdifferenzierungsfaktor 15
WO2020186247A1 (en) 2019-03-13 2020-09-17 University Of Virginia Patent Foundation Compositions and methods for promoting islet viability and enhancing insulin secretion
CN110151980B (zh) * 2019-06-30 2022-12-09 中国药科大学 Glp-1受体激动剂融合蛋白在制备预防或治疗高血脂药物中的应用
PE20221575A1 (es) 2020-02-18 2022-10-06 Novo Nordisk As Formulaciones farmaceuticas
WO2022157747A2 (en) 2021-01-25 2022-07-28 Mylan Ireland Limited Pharmaceutical peptide compositions and methods of preparation thereof
CN114028537B (zh) * 2021-11-27 2024-03-29 上海万锦医药科技有限公司 一种含有svhrsp蝎毒肽的药物组合物及其制备方法
WO2024123812A1 (en) 2022-12-05 2024-06-13 Shattuck Labs, Inc. Fusion proteins for the treatment of cardiometabolic diseases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
BR9407424A (pt) 1993-09-07 1996-04-09 Amylin Pharmaceuticals Inc Métodos para regular motilidade gastrointestinal
AU723694B2 (en) * 1996-06-05 2000-08-31 Roche Diagnostics Gmbh Exendin analogues, processes for their preparation and medicaments containing them
DE69739172D1 (de) 1996-08-08 2009-01-29 Amylin Pharmaceuticals Inc Regulation gastrointestinaler beweglichkeit
JP3149958B2 (ja) * 1996-08-30 2001-03-26 ノボ ノルディスク アクティーゼルスカブ Ｇｌｐ―１誘導体
RU2114617C1 (ru) * 1996-09-27 1998-07-10 Юрий Георгиевич Каминский Антидиабетическое средство на основе янтарной кислоты
PT1629849E (pt) 1997-01-07 2013-07-09 Amylin Pharmaceuticals Llc Composições farmacêuticas que compreendem exendinas e seus agonistas
DK1019077T4 (da) 1997-08-08 2011-03-07 Amylin Pharmaceuticals Inc Hidtil ukendte exendinagonistforbindelser
JP2001523688A (ja) 1997-11-14 2001-11-27 アミリン・ファーマシューティカルズ，インコーポレイテッド 新規エキセンジン・アゴニスト化合物
JP2003522721A (ja) 1997-11-14 2003-07-29 アミリン・ファーマシューティカルズ，インコーポレイテッド 新規なエキセンジンアゴニスト化合物
ATE366115T1 (de) 1998-02-13 2007-07-15 Amylin Pharmaceuticals Inc Inotropische und diuretische effekte von exendin und glp-1
WO1999043708A1 (en) * 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
US6506724B1 (en) * 1999-06-01 2003-01-14 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
US6528486B1 (en) * 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity

Also Published As

Publication number Publication date
DE60021166T3 (de) 2019-08-22
JP4426727B2 (ja) 2010-03-03
EP1140145B1 (de) 2005-07-06
NO2012008I2 (no) 2012-05-09
AU2005200206A1 (en) 2005-02-10
JP2002534450A (ja) 2002-10-15
WO2000041546A9 (en) 2001-03-08
US6902744B1 (en) 2005-06-07
PT1140145E (pt) 2005-11-30
AU2005200206B2 (en) 2007-02-15
DE122007000001I1 (de) 2007-06-28
NL300282I1 (nl) 2007-09-03
AU3581900A (en) 2000-08-01
EP1609478A1 (de) 2005-12-28
EP1140145A2 (de) 2001-10-10
DE122007000042I2 (de) 2011-05-05
EP1140145B2 (de) 2019-05-15
CA2356706A1 (en) 2000-07-20
BRPI0007820B8 (pt) 2021-05-25
DE122007000042I1 (de) 2008-04-24
CN100356978C (zh) 2007-12-26
NO331382B1 (no) 2011-12-12
DK1140145T4 (da) 2019-07-22
DK1140145T3 (da) 2005-10-24
CA2356706C (en) 2014-09-30
HK1040635B (en) 2005-09-02
KR20010086165A (ko) 2001-09-08
DE60021166D1 (de) 2005-08-11
LU91343I2 (fr) 2007-12-06
BRPI0007820B1 (pt) 2016-01-26
NO2012008I1 (no) 2012-05-21
RU2242244C2 (ru) 2004-12-20
CN101181236A (zh) 2008-05-21
CY2007013I1 (el) 2011-02-02
ES2244416T3 (es) 2005-12-16
KR100675711B1 (ko) 2007-02-01
AU777564B2 (en) 2004-10-21
HK1040635A1 (en) 2002-06-21
NZ512663A (en) 2004-05-28
BR0007820A (pt) 2001-11-20
DE60021166T2 (de) 2006-04-27
CY2007013I2 (el) 2011-02-02
NO20013468L (no) 2001-09-14
NO20013468D0 (no) 2001-07-12
ES2244416T5 (es) 2020-01-03
WO2000041546A2 (en) 2000-07-20
CN1384755A (zh) 2002-12-11
WO2000041546A3 (en) 2000-11-30

Similar Documents

Publication Publication Date Title
DE60021166D1 (de) Neue exendin agonist formulierungen und deren verabreichung
BR9814189A (pt) "compostos agonistas da exendina"
BR9815670A (pt) Compostos agonistas de exendina
DK1129093T3 (da) Pyrazolopyrimidinonderivater til behandling af impotens
NO20100302L (no) Sammensetninger som inneholder organiske forbindelser
ATE322265T1 (de) Pharmazeutische zusammensetzung zur behandlung von kolorektalem krebs welche thalidomid und irinotecan enthält
DK1057828T3 (da) Orale trovafloxacin-suspensioner
DE50210906D1 (de) Arzneimittel enthaltend deuterium zur behandlung der zuckerkrankheit
WO2002094189A3 (en) Compositions and methods for treating or preventing convulsions or seizures
UY28953A1 (es) Derivados heterocíclicos para el tratamiento de hiperlipidemia y enfermedades relacionadas
BRPI0409609A (pt) mediadores do transporte reverso de colesterol para o tratamento da hipercolesterolemia
AR012457A1 (es) Proceso para preparar una composicion de asfalto
DK1079840T3 (da) Synergistisk præparat af inulin og et anticancerlægemiddel til anvendelse til behandling af cancer
DE60039122D1 (de) 6-o-alkyl-2-nor-2-substituierte ketolidderivate
CL2004001461A1 (es) Compuestos derivados de 1,2,3,4-tetrahidropirimidina, composicion farmaceutica y su procedimiento de preparacion, procedimiento de preparacion, utiles para tratar o prevenir la hepatitis c.
TH83718B (th) " วิธีการและองค์ประกอบสำหรับยับยั้งการติดเชื้อจาก Helicobacter Pylori โดยการรับโปรไซยานิดินชนิด B และ C "
RU2002106907A (ru) Способ лечения туберкулеза
FI20010097L (fi) Askorbaattia ja lysiiniä synergistisiä koostumuksia niitä tiloja varten, jotka liittyvät soluvälineen degeneraatioon
TR199901567T2 (xx) Asetobakter cinsi bakteriler i�eren farmas�tik ve g�dasal bile�imler